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PURPOSE. Conjunctival melanoma (CM) is a rare disease associated with considerable mortality.
As opposed to cutaneous melanoma, the epigenetic mechanisms involved in the development
of CM and other mucosal melanomas (MMs) are unclear. The purpose of this study was to
identify tumor-specific and prognostic microRNA (miRNA) in CM and to compare the miRNA
profile with that of MM.
METHODS. Using microarray analysis (Affymetrix) we determined the miRNA expression
profile in 40 CMs compared with 7 normal conjunctival samples. Changes in miRNA
expression were associated with T stage, local recurrence, metastasis, and mortality.
Furthermore, the expression of six fresh frozen tissue samples of CM was compared with that
of four laryngeal and sinonasal MM.
RESULTS. Our analysis revealed 24 upregulated and 1 downregulated miRNA in CM; several of
these miRNAs have key functions in the pathogenesis and progression of cutaneous
melanoma. Additionally, we identified seven upregulated miRNAs specific for stage-T1 and
stage-T2 CM, whose expression was associated with increased tumor thickness (P ¼ 0.007),
and two upregulated miRNAs (miR-3687 and miR-3916) associated with an increased risk of
local recurrence. No stage T3–specific miRNAs were identified.
CONCLUSIONS. We identified differentially expressed and potentially prognostic miRNAs in CM.
Furthermore, the miRNA expression pattern of CM resembled that in MM. The identification
of these differentially expressed miRNAs provides an entry point for future functional studies
of miRNAs as prognostic or therapeutic targets in CM and highlights the resemblance
between CM, MM, and cutaneous melanoma.
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Conjunctival melanomas (CMs) account for approximately5% of ocular melanomas and they have an associated
mortality of up to 30%.1,2 Recently, oncogenic mutations in
BRAF, NRAS, and KIT have been identified in CM, emphasizing
their close genetic resemblance to cutaneous and mucosal
melanomas (MMs), and their difference from uveal melanomas
(UMs).2–5 Owing to the high mortality rate associated with CM
and MM,2,6 there is a need to further identify molecular
pathways that drive development and progression. MicroRNAs
(miRNAs) are small noncoding RNA molecules that epigenet-
ically regulate gene expression at the posttranscriptional level
by either degradation of or translational blockage of target
messenger RNAs.7 Deregulation of miRNAs with oncogenic and
tumor-suppressive functions have attracted much attention
owing to their high prevalence.8 These small miRNA molecules
could be used as prognostic or therapeutic targets. A micro-
array-based miRNA expression profiling platform was therefore
used to compare the expression of miRNAs in archived
(formalin-fixed, paraffin-embedded [FFPE]) CM and normal
conjunctival samples. The miRNA expression pattern in CM
was tested for associations with TNM stage,9 local recurrence,
metastasis, and mortality in order to identify prognostic
miRNAs. To determine similarities in miRNA expression
between CM and different subtypes of MM, fresh frozen tissue
samples from CM, sinonasal MM, and laryngeal MM were
analyzed and the miRNA expression results were compared.
MATERIALS AND METHODS
Patients and Tissue Samples
Patients diagnosed with CM were identified by searching the
archives of the Eye Pathology Institute and the Danish Registry
of Pathology. Archived (2000–2012) and fresh frozen (2000–
2014) tissue samples were collected. Archived tissue samples
from normal conjunctiva were collected from the Eye
Pathology Institute (1999–2000) from patients with no history
of a pigmented lesion. Fresh frozen tissue samples from
sinonasal and laryngeal MM patients were identified and
obtained from the Danish Registry of Pathology and the Danish
Cancer Biobank (2000–2014).
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Information on patient and tumor characteristics, clinical
presentation, local recurrence, regional and distant metastases,
and cause of death was obtained from clinical patient records,
from pathology reports, and by searching the Danish Registry
of Pathology and the Danish Register of Causes of Death, as
previously described.2,10 The proliferative index (mitotic rate)
was evaluated in slides stained with anti–Ki-67 (Dako Den-
mark, Glostrup, Denmark) and the percentage of Ki-67–
positive cells was assessed. All of the CMs were divided into
two groups (15% and >15%). TNM staging was based on
clinical information available and was performed according to
the American Joint Commission on Cancer TNM classification,
seventh edition.9
We obtained sufficient archived FFPE tumor material from
40 of 55 CM samples and from 7 normal conjunctival samples.
Fresh frozen tumor samples were obtained from six CMs, three
sinonasal melanomas, and one laryngeal melanoma. Archived
CM samples were evaluated with hematoxylin-eosin– and
Melan-A–stained slides to establish the amount of tumor tissue.
Then 8 to 10 sections, each of 20-lm thickness, were cut.
When the amount of tumor tissue in the sample was evaluated
to be <80% to 90%, the sections were transferred to glass slides
and tumor tissue was macrodissected by hand with a scalpel.
The study adhered to the tenets of the Declaration of Helsinki.
Ethical Committee approval was obtained and the study was
approved by the Danish Data Protection Agency.
RNA Isolation
For automated purification of total RNA from FFPE tissue, we
used the QIAsymphony RNA Kit according to the manufactur-
er’s instructions (Qiagen, Valencia, CA, USA). For purification
of total RNA (including small RNAs) from fresh frozen tumor
samples, the AllPrep DNA/RNA Micro Kit was used according
to the manufacturer’s instructions (also Qiagen). The degree of
RNA degradation was evaluated before microarray analysis by
using the Agilent RNA 6000 Nano Kit on an Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Microarray Profiling Analysis
One hundred thirty micrograms of total RNA was prepared
from each sample and hybridized on a GeneChip 4.0 Array
(Affymetrix, Santa Clara, CA, USA), according to the manufac-
turer’s instructions. Briefly, total RNA was labeled with
FlashTag Biotin HSR by Poly(A) tailing and subsequent FlashTag
Biotin HSR ligation, and incubated at 998C for 5 minutes and
458C for 5 minutes with Hybridization Master Mix. Arrays were
hybridized at 488C and 60 rpm for 16 to 18 hours in an
Affymetrix 640 Hybridization oven, and washed and stained
with phycoerythrin-conjugated streptavidin in an Affymetrix
450 Fluidics Station. The arrays were scanned in an Affymetrix
GeneChip Scanner 3000 to generate fluorescent images, as
described in the Affymetrix Gene Chip protocol. Cell intensity
files were generated with GeneChip Command Console
software (AGCC) (Affymetrix). Cell intensity files were RMA-
normalized with the Affymetrix Expression Console, and 2578
probe sets representing human mature miRNAs were selected
for further analysis. The expression matrix was imported into
the R environment11 and differential expression between
samples was defined with eBayes modeling, as implemented
in the R LIMMA package.12 MicroRNAs were defined as
showing differential expression if fold changes were above 2
and Benjamini-Hochberg-adjusted P values (false discovery
rate) were below 0.1. Differentially expressed miRNAs were
visualized by using hierarchical clustering based on average
linkage and Euclidian distance, as implemented in Qlucore
Omics Explorer (www.qlucore.com; provided in the public
domain by Qlucore, Lund, Sweden).
Analysis of Archived Tissue Samples
For the analysis of miRNA expression in CMs from archived
tissue, three heavily pigmented CMs were excluded because
miRNA signals were disturbed. This resulted in the inclusion of
37 CM samples for further analysis. For the identification of
tumor-specific miRNAs, all pooled tumor samples were
compared to normal conjunctiva. For the identification of
prognostic miRNAs, tumors of TNM stages T1, T2, and T3 were
compared to normal conjunctiva. In addition, the associations
of each miRNA with local recurrence, distant metastasis, any
metastasis (regional or distant), and melanoma-related mortal-
ity were tested by Cox regression analysis, as implemented in
the R survival package. v2 and Kruskal-Wallis tests were used to
compare patient characteristics and tumor features with
clusters of low, intermediate, and high miRNA expression.
Statistical calculations were performed by using SPSS (version
20; IBM, Armonk, NY, USA).
Analysis of Fresh Frozen Tumor Samples
Fresh frozen tissue samples were analyzed as an additional part
of the study. Expression analysis was performed as described
for archived tissue, and the expression of tumor-specific
miRNAs was compared to CM, sinonasal MM, and laryngeal
MM. In three CM patients, miRNA expression results were
obtained from both fresh frozen and archived tissue samples.
We were therefore able to measure the correlation coefficient
(r) between miRNA expression from fresh frozen CM samples
and archived CM samples by using Pearson product-moment
correlation analysis.
RESULTS
Patient and Tumor Characteristics
MicroRNA expression results were obtained in 37 consecutive
CM patients, 17 men and 20 women, with a median age of 72
years (range, 37–92 years). The median follow-up period was
3.7 years (range, 5 months–13 years). The tumors were most
commonly epibulbar (27/37), and local invasion to eyelid skin
occurred in four cases. The tumors were staged as T1 (27), T2
(6), and T3 (4). Median tumor thickness was 1.2 mm (range,
0.2–8.0 mm); the CM most commonly originated in a primary
acquired melanosis with atypia (PAMþ) (30/37), and a third of
the CMs (12/37) were BRAF mutated (Table 1). There was local
recurrence in 14/37 cases (38%), regional metastasis was
recorded in three patients, and distant metastasis developed in
five patients. At the end of follow-up, 4 patients had died from
melanoma-related causes, 12 patients had died from other
causes, 2 patients had died from unknown causes, and 19
patients were still alive.
Differentially Expressed miRNAs in Conjunctival
Melanoma
We identified 25 miRNAs in CM that were differentially
expressed relative to normal conjunctiva (24 upregulated and
1 downregulated) (Table 2). We performed a supervised
hierarchical cluster analysis of the 25 differentially expressed
miRNAs. Six of seven of the normal tissue samples clustered
closely together, with low expression of 24 miRNAs and high
expression of 1 miRNA. The tumor samples were clustered
according to expression levels and showed a gradient of
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increased expression from melanomas resembling normal
tissue to a highly upregulated expression pattern of 24 miRNAs
and downregulated expression of 1 miRNA.
Prognostic Significance of Differentially
Expressed miRNAs
To determine the prognostic associations of differentially
expressed miRNAs, stage-specific miRNAs were identified
(Fig. 1). Seven miRNAs (miR-30d-5p, miR-138-5p, miR-146a-
5p, miR-500a-5p, miR-501-3p, miR-501-5p, and miR-502-3p)
were significantly and simultaneously upregulated in both
stage-T1 and stage-T2 CM relative to normal conjunctiva
(Table 2). A 2-way cluster analysis based on these seven
differentially expressed miRNAs distinguished the samples in
clusters of low expression (n ¼ 11), intermediate expression
(n ¼ 12), and high expression (n ¼ 14) (Fig. 1). Six of seven
(85%) of the normal conjunctival samples clustered in the
low expression group. The tumors showed a gradient
increase from low expression to high expression. In
particular, 14 CM samples showed a high expression
pattern. These were significantly thicker (mean thickness
of 2.7 mm) than 12 tumors with intermediate expression
and 11 tumors with low expression (mean tumor thickness
of 1.0 and 1.2 mm, respectively) (P ¼ 0.007, Kruskal-Wallis).
Additionally, the CMs with a high expression pattern tended
to have a higher Ki-67 proliferative index (P ¼ 0.052). No
other demographic features or tumor characteristics were
significantly associated with the expression patterns ob-
served. Expression of a single miRNA (miR-5096) was
downregulated in T2 tumors relative to normal conjunctiva.
No significant difference in miRNA expression was identified
when we compared stage-T3 tumors (n ¼ 4) with normal
conjunctiva.
An upregulated expression of miR-3687 and miR-3916 was
associated with a higher risk of local recurrence in CM (Table
3). None of the miRNAs were significantly associated with
metastasis, or with melanoma-related mortality.
MicroRNA Expression in Conjunctival Melanomas
and in Other Mucosal Melanomas
Fresh frozen tissue samples were obtained from six CMs,
three sinonasal MMs, and one laryngeal MM. A highly
TABLE 1. Demographic, Clinicopathologic, and Genetic Characteristics of 37 Consecutive Conjunctival Melanoma Patients Who Were Tested for
Associations With Expression of Tumor-Specific miRNAs
Characteristic Total Patients, No. (%)
MicroRNA Expression Group,* No. (%)
P Value†Low Intermediate High
Sex
Male 17 (46) 4 (36) 5 (42) 8 (57) 0.55
Female 20 (54) 7 (64) 7 (58) 6 (43)
Age, mean (95% CI), y 70 (64–75) 71 (60–82) 69 (58–79) 70 (60–80) 0.86
Tumor location
Epibulbar 27 (73) 7 (64) 11 (92) 9 (64) 0.26
Extrabulbar 9 (24) 3 (27) 1 (8) 5 (36)
Caruncular 1 (3) 1 (9) 0 0
Local invasion to eyelid skin
Present 4 (11) 2 (18) 1 (8) 1 (7) 0.64
Absent 33 (89) 9 (82) 11 (92) 13 (93)
TNM stage‡
T1 27 (73) 7 (64) 11 (92) 9 (64) 0.29
T2 6 (16) 2 (18) 0 4 (29)
T3 4 (11) 2 (18) 1 (8) 1 (7)
Tumor thickness, mean (95% CI), mm 1.6 (1.2–2.2) 1.0 (0.5–1.5) 1.2 (0.6–1.7) 2.7 (1.6–3.8) 0.007
Cell type
Epithelioid 16 (43) 2 (18) 8 (67) 6 (43) 0.16
Mixed 18 (49) 7 (64) 4 (33) 7 (50)
Spindle 3 (8) 2 (18) 0 1 (7)
Ki-67 proliferative index
15, low 21 (62) 8 (89) 8 (67) 5 (48) 0.052
>15, high 13 (38) 1 (11) 4 (33) 8 (62)
Origin
PAMþ 30 (81) 11 (100) 10 (84) 9 (64) 0.26
Nevus 4 (11) 0 1 (8) 3 (22)
De novo 3 (8) 0 1 (8) 2 (14)
BRAF
Mutated 12 (32) 1 (9) 5 (42) 6 (43) 0.14
Wild-type 25 (68) 10 (91) 7 (58) 8 (57)
* Low, intermediate, or high expression of seven upregulated microRNAs identified in conjunctival melanoma.
† Fisher’s exact test, v2 test, or Kruskal-Wallis test as appropriate.
‡ None of the patients had nodal or distant metastasis at the time of diagnosis.
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significant correlation in expression patterns from fresh
frozen CM samples and archived CM samples from three
patients was observed, with Pearson correlation coefficients
(r) of 0.85 (95% confidence interval [CI]: 0.84–0.86, P < 2.2
3 10-16), 0.91 (95% CI: 0.90–0.91, P < 2.2 3 10-16), and
0.93 (95% CI: 0.92–0.93, P < 2.2 3 10-16). Most of the CMs
were from female patients. The patient ages ranged from 34
to 92 years, and the tumors were most frequently located in
the epibulbar region. Three of four sinonasal and laryngeal
MM patients were males, and patient age ranged from 65 to
87 years (Table 4). No significant difference in expression
was identified when comparing the expression of the 25
differentially expressed miRNAs (upregulated in CM relative
to normal conjunctiva) with the miRNA expression results
obtained from sinonasal and laryngeal MMs (Fig. 2).
DISCUSSION
Recently, the identification of BRAF, NRAS, and KIT mutations
in CM has shown a striking difference from UMs and has
highlighted the genetic resemblance with both cutaneous and
mucosal melanoma.2–5,13,14 Identification of diagnostic, prog-
nostic, or therapeutic miRNAs has the potential to improve the
prognosis for both cutaneous melanoma patients and UM
patients.15–18 However, to the best of our knowledge, no
previous reports on miRNA expression in CM and head and
neck MM have been published.
The CM patients included in the present study had a sex
ratio of approximately 1:1, and apart from having a slightly
higher age on average at diagnosis, the present data may be
regarded as being representative of CM.2,19,20
TABLE 2. MicroRNAs With Significantly Different Expression in CM and Normal Conjunctiva (Normal), miRNAs With Significantly Different
Expression in CM Stages T1 and T2 Relative to Normal, and Associations With miRNA Expression Observed in Cutaneous Melanoma
miRNA Conjunctival
Melanoma Fold Change P Value*
Reference—miRNAs Associated
With Cutaneous Melanoma
CM vs. normal
Hsa-miR-3689 4.1 7.5 3 106
Hsa-miR-181b-5p 13.3 1.4 3 105
Hsa-miR-132-3p 4.9 2.1 3 105 Pinto et al.27
Hsa-miR-510-5p 8.2 2.9 3 105
Hsa-miR-138-5p 21.6 3.3 3 105 Poliseno et al.28
Hsa-miR-363-5p 10.0 7.7 3 105 Philippidou et al.26
Hsa-miR-345-5p 4.5 8.1 3 105
Hsa-miR-4689 2.1 0.0001
Hsa-miR-181a-2-3p 6.2 0.0002
Hsa-miR-501-3p 4.9 0.0002
Hsa-miR-146b-5p 6.0 0.0002 Chen et al.21; Philippidou et al.26; Poliseno et al.28;
Saleiban et al.15; Sand et al.30
Hsa-miR-509-3p 272.4 0.0002 Saleiban et al.15; Streicher et al.16
Hsa-miR-146a-5p 74.4 0.0002 Forloni et al.23; Philippidou et al.26; Poliseno et
al.28; Qi et al.29; Raimo et al.31
Hsa-miR-500a-5p 5.8 0.0003
Hsa-miR-509-3-5p 24.4 0.0003 Saleiban et al.15
Hsa-miR-532-3p 4.8 0.0004
Hsa-miR-181a-5p 9.0 0.0004 Poliseno et al.28
Hsa-miR-500b-3p 4.7 0.0005 Saleiban et al.15
Hsa-miR-20b-5p 7.0 0.0005 Saleiban et al.15; Xu et al.18
Hsa-miR-506-3p 14.1 0.0006 Streicher et al.16
Hsa-miR-128-3p 5.0 0.0007
Hsa-miR-532-5p 5.1 0.0007 Kitago et al.25; Saleiban et al.15
Hsa-miR-502-3p 5.6 0.0007
Hsa-miR-1260b 4.2 0.001
Hsa-miR-501-5p 5.4 0.001 Saleiban et al.15
T1 and T2 vs. normal†
Hsa-miR-138-5p 9.0 3.5 3 105 Poliseno et al.28
Hsa-miR-501-3p 3.5 4.4 3 105
Hsa-miR-146a-5p 11.1 9.4 3 105 Forloni et al.23; Philippidou et al.26; Poliseno et
al.28; Qi et al.29; Raimo et al.31
Hsa-miR-30d-5p 4.4 0.0002 Fleming et al.22; Gaziel-Sovran et al.24; Philippidou
et al.26; Poliseno et al.28
Hsa-miR-502-3p 4.1 0.0003
Hsa-miR-500a-5p 3.6 0.0003
Hsa-miR-501-5p 3.9 0.0003 Saleiban et al.15
Positive fold changes represent upregulation and negative fold change represents downregulation of miRNA expression in tumors relative to
normal tissue. MicroRNAs in bold have been reported previously in cutaneous melanoma.
* Significantly expressed miRNAs were identified after application of a false discovery rate less than 0.1 and a fold change of 2.0 or greater.
† T stages were designated according to the American Joint Commission on Cancer TNM classification (7th edition), and the reported P values
and fold changes were from the comparison of tumor stage T2 with normal.
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FIGURE 1. MicroRNAs with a significantly different degree of expression between CM stage T1, T2, and T3 and normal conjunctiva (false discovery
rate < 0.1, fold change > 2). (A) Nodular melanoma of the palpebral conjunctiva (stage T2) with melanosis of the lid margin and plica semilunaris.
(B) Conjunctival melanoma with a tumor thickness of 2.5 mm. Hematoxylin-eosin, original magnification 32.5. (C) Venn diagram showing seven
upregulated miRNAs (miR-30d-5p, miR-138-5p, miR-146a-5p, miR-500a-5p, miR-501-3p, miR-501-5p, and miR-502-3p) overlapping between stage-T1
and stage-T2 CM, and a single downregulated miRNA (miR-5096) in stage-T2 CM. (D) Hierarchical cluster visualization of the seven significantly
upregulated miRNAs divided the CM in groups of low, intermediate, and high expression.
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In the present study, we performed an expression analysis
of 2578 mature human miRNAs and identified 24 significantly
upregulated miRNAs and 1 significantly downregulated miRNA
in CM versus normal conjunctiva. Whereas several of these
miRNAs have previously been described in cutaneous melano-
ma,15,16,18,21–31 none have been reported previously in UM
samples.17,32,33 It was not possible to collect paired normal
tissue for the comparison with CM, which may have limited the
number of significant miRNAs identified in the present study.
We observed an upregulation of miR-20b-5p (miR-20b) in
primary CM samples. This miRNA has previously been
characterized as an oncomiR in cutaneous melanoma, and
has been reported to be upregulated in primary and metastatic
cutaneous melanoma.18,34 In another study, downregulation of
miR-20b in metastatic cutaneous melanoma has been associat-
ed with activation of proteinase-activated receptor-1 (PAR-1),
which is involved in tumor invasion and angiogenesis—and
consequently tumor metastasis.15,35 Owing to this dual
function of miR-20b, further investigations are needed to
establish the prognostic and therapeutic potential of miR-20b
in CM. Another interesting observation was the upregulation of
miR-146a-5p (miR-146/miR-146a) and miR-146b-5p (miR-146b)
in CM. Upregulation of miR-146a has been observed in primary
and metastatic cutaneous melanoma, and it may be specific for
metastatic disease.26,29,31 miR-146a promotes both initiation
and progression of BRAF/NRAS-mutated cutaneous melanoma
through increased activation of the NOTCH protein.23
NOTCH1 is involved in melanoma formation and may enhance
the metastatic potential of primary melanoma cells through
activation of the mitogen-activated protein kinase (MAPK)
pathway or the PI3K/Akt pathway.36 Upregulation of miR-146b
expression has consistently been reported in cutaneous
melanoma and appears to be associated with melanoma
progression.15,21,26,30 It is therefore evident that miR-146a
and miR-146b have oncogenic roles in cutaneous melanoma,
and these miRNAs may have a similar role in CM. The observed
upregulation of miR-506-3p (miR-506) and miR-509-3p (miR-
509) belonging to the miR- 506-514 cluster has also been
described in metastatic cutaneous melanoma.15,16 In functional
characterization of the miR-506-514 cluster, inhibition of the
cluster has led to reduced cell growth and invasion and
increased apoptosis in melanoma cell lines.16 Inhibition of
these miRNAs may therefore be a new approach in the
treatment of cutaneous melanoma and possibly CM.
To identify possible prognostic miRNAs, we analyzed the
miRNA expression in TNM stages T1, T2, and T3 and compared
the profiles with that for normal conjunctiva. We observed that
upregulation of seven miRNAs shared by stage-T1 and stage-T2
CM divided the CM in clusters of low, intermediate, and high
expression and that an increased expression was associated
with increased tumor thickness, which is a known feature of
poor prognosis in CM.37–39 One of the differentially expressed
miRNAs specific for T1 and T2 tumors was miR-30d, which has
been reported to have upregulated expression in metastatic
cutaneous melanoma cell lines. Furthermore, upregulation of
this miRNA correlates with increased tumor thickness,
invasion, metastasis, and mortality in cutaneous melanoma
patients.24,26 In addition, miR-30d targets several messenger
RNAs involved in melanoma and/or cancer progression (MITF,
ITGA5, SERPINE1, and ADAM19).22
Downregulation of miR-5096, which has not been reported
previously in melanoma, was identified in stage-T2 tumors
relative to normal conjunctiva. We did not identify differen-
tially expressed miRNAs specific for T3 tumors, which may
have been because of the small number of stage-T3 cases in the
present study. To accurately detect stage-specific miRNAs,
future studies should therefore include more T2 and T3
tumors.
The differences in tumor thickness observed may have been
because the thinner tumors were more difficult to macro-
dissect. Thus, these samples may have had a higher proportion
of normal tissue that interfered with the expression results.
Microdissection of CM samples or the use of CM samples > 2
mm in thickness is therefore recommended for future studies.
Upregulation of two specific miRNAs (miR-3687 and miR-
3916) was associated with a higher risk of local recurrence in
CM patients. These miRNAs have not previously been
described to be associated with melanoma development and/
or progression. The lack of miRNAs significantly associated
with metastasis or mortality may have been caused by the low
number of patients developing metastasis and dying of
melanoma-related causes in the present study.
Formalin-fixed, paraffin-embedded tumor samples are a
readily available source of material for retrospective analyses.
However, the degree of RNA degradation during the process of
formalin fixation and its influence on miRNA expression levels
have not been investigated in CM. Using tissue samples from
TABLE 3. MicroRNAs Associated With an Increased Risk of Local
Recurrence in Cox Regression Analysis
MicroRNA Cox Coefficient Cox P Value*
Hsa-miR-3687 2.14 5.20 3 105
Hsa-miR-3916 4.46 3.96 3 106
* Significantly expressed miRNAs were identified after application
of a false discovery rate less than 0.1 and a fold change of 2.0 or greater.
TABLE 4. Clinicopathologic Characteristics of Conjunctival (n¼6) and Other Head and Neck Mucosal Melanomas (n¼4) (Fresh Frozen Specimens)
Case Age, y Sex Melanoma Type Location Tumor Thickness, mm TNM*
1 88 F Conjunctival Epibulbar 2 T1
2 71 F Conjunctival Extrabulbar 3.5 T2
3 49 F Conjunctival Extrabulbar, eyelid skin 1 T3
4 34 M Conjunctival Epibulbar 10 T1
5 81 F Conjunctival Epibulbar 3 T1
6 92 F Conjunctival Epibulbar 5 T1
7 76 M Mucosal Nasal cavity – T4
8 87 M Mucosal Nasal cavity, nasopharynx,
maxillary sinus
– T4
9 83 M Mucosal Nasal cavity – T3
10 65 F Mucosal Larynx 10 T3
Abbreviations: M, male; F, female.
* Tumors were classified according to the American Joint Commission on Cancer TNM classification (7th edition). None of the patients had nodal
or distant metastatic disease at the time of diagnosis.
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three patients, we were able to compare miRNA results from
fresh frozen tissue and archived tissue from the same tumors.
There was a good correlation between miRNA expression
levels measured from FFPE CM samples and from fresh frozen
CM samples, indicating that archived tissue is reliable for
analysis of miRNA expression in CM.
Using fresh frozen tissue, we extended the study and
investigated similarities in miRNA expression profiles between
different subtypes of MM. No significant variation in expres-
sion of 25 tumor-specific miRNAs was observed between CM,
sinonasal MM, and laryngeal MM. Owing to a low number of
available fresh frozen tissue samples, this study was limited by
the inclusion of mainly stage-T1 and stage-T2 CM, which was
compared to stage-T3 and stage-T4 sinonasal and laryngeal
melanoma. The subtypes of melanoma that we investigated all
develop in mucosal membranes, and the miRNA expression
may therefore also reflect shared embryologic or tissue-specific
properties.
In conclusion, the novel finding in our study is a description
of several miRNAs in CM. Many of these have previously been
reported in cutaneous melanoma, and some may be potential
prognostic biomarkers or possible future targets for therapy.
Interestingly, no significant variation in the expression pattern
of these miRNAs was observed when comparing different
subtypes of MM. Thus, the miRNA expression in CM appears to
be closely related to that of both cutaneous melanoma and
other MMs. The miRNAs identified in the present study have
not been described previously in CM and they warrant further
investigation and validation.
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